As treatment response can mimic progressive tumor on standard imaging, clinical outcomes following upfront chemo-radiotherapy in newly diagnosed glioblastoma rely heavily on MGMT promoter methylation status. While MGMT is a reliable marker of outcomes, the purpose of this study was to determine if inclusion of advanced perfusion-MRI derived fractional tumor burden (FTB) volume might better inform survival outcomes. Results revealed that low FTB volume in MGMT unmethylated glioblastoma confers significant survival benefit, approaching that of MGMT methylated glioblastoma. Clinically, combining FTB with MGMT methylation status may identify patients with potentially better outcomes or for whom more aggressive approaches are warranted.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords